ADL Launches Revolutionary Urine-Based Diagnostic Test To Detect Precursor To Deadly Colorectal Cancer

Monday, June 27, 2016 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

PHILADELPHIA, June 27, 2016 /PRNewswire/ -- Atlantic Diagnostic Laboratories (ADL), today announced the official launch of

PolypDx, a non-invasive urine-based diagnostic test for detection of adenomatous polyps, the precursor to colorectal cancer.  It is estimated that there will be 134,490 new cases reported this year. With early detection in the adenomatous
polyp stage, this form of cancer is preventable.  Early detection will save lives and reduce treatment costs.

"ADL, with its extensive LC/MS/MS expertise, is very excited to be offering the PolypDx non-invasive urine test for its official launch into America," said Aaron Domenico, Chief Operating Officer of ADL. "Colorectal cancer is a leading cause of death in the United States.  With early detection in the adenomatous polyp stage, this form of cancer is preventable."

PolypDx gives doctors a new tool in the prevention of colorectal cancer.  In a Canadian-based clinical trial of nearly 1,000 patients, MTI's PolypDx demonstrated significantly higher sensitivity than current fecal-based screening tests to detect adenomatous polyps.  Once screened, patients presenting a risk of adenomatous polyps can be directed to a colonoscopy, during which the adenomatous polyps can be completely and safely removed, thus preventing the progression into colorectal cancer.  PolypDx is a simple and effective test requiring only a small urine sample.  Early detection and non-invasive ease of use are key distinguishing factors for a screening test in the prevention of colorectal cancer.

PolypDx is the flagship product of Metabolomic Technologies Inc. (MTI), a privately held Canadian company based in Edmonton, Alberta.  MTI has signed a multi-million dollar agreement with ADL giving them the exclusive licensing and distribution rights to bring PolypDx into the US market.

"The partnership and collaboration between MTI and Atlantic Diagnostic Laboratories will provide the opportunity for patients to access a simple and accurate test with proven capacity to detect adenomatous colonic polyps and thereby prevent colon cancer," said Dr. Richard Fedorak, President of MTI.

ADL is a full service clinical laboratory with headquarters in the suburbs of Philadelphia providing microbiology, chemistry, toxicology, immunology, virology and molecular testing in 12 states: Pennsylvania, New Jersey, Connecticut, New York, District of Columbia, Delaware, Maryland, Virginia, Florida, Ohio, Kentucky and West Virginia.

About Atlantic Diagnostic Laboratories, LLC (ADL):Atlantic Diagnostic Laboratories, LLC (ADL) is a U.S.-based independent full service clinical laboratory providing microbiology, chemistry, toxicology, immunology, and virology testing used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of diseases.  It has also developed niche operations based on certain types of specialized testing capabilities providing insights that empower and enable medical professionals to make better healthcare decisions.  ADL is fully accredited by the College of American Pathologists (CAP) for clinical and forensic studies.

Media Contact:Lisa Johnson Communications   

About Metabolomic Technologies Inc. (MTI):Metabolomic Technologies Inc. (MTI) is a privately held Canadian company based in Edmonton, Alberta.  A spin-off from the University of Alberta, MTI focuses on the development of metabolomics-based diagnostic systems created from proprietary biomarker technologies.  The Company's flagship product, PolypDx, an innovative urine diagnostic test, offers a significantly higher sensitivity in detecting adenomatous polyps, a precursor to colorectal cancer (CRC). PolypDx provides healthcare professionals with a tool for early screening and detection over less effective fecal-based screening methodologies considered suboptimal due to a lack of sensitivity and acceptability.

MTI is committed to developing high value diagnostic tests for the management of chronic disease.  The Company received the North American Frost & Sullivan Award for Technology Innovation Leadership in 2014.

Media Contact:David Chang,

To view the original version on PR Newswire, visit:

SOURCE Atlantic Diagnostic Laboratories, LLC (ADL)

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store